| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
Levosimendan is a new calcium sensitizer developed for the short-term intravenous treatment of congestive heart failure. The aims of the present open-label, nonrandomized study were to determine the tolerability, hemodynamic effects, and the basic pharmacokinetics of levosimendan and its metabolites during an extended continuous infusion of levosimendan. Twenty-four patients with New York Heart Association (NYHA) III-IV heart failure in two groups of 12 patients were exposed to either 0.05 microg/kg/min or 0.1 microg/kg/min of levosimendan for 7 days. Heart rate and blood pressure were measured, and blood samples for the determination of plasma concentrations of the parent drug and its metabolites were drawn daily during the infusion and the 10 to 15 days' follow-up. The 7-day infusion was well tolerated and no premature discontinuations occurred. Both systolic and diastolic blood pressure decreased maximally by 6 mmHg in the lower and by 11 mmHg in the higher levosimendan dose groups during the infusion period (p < 0.05 for both groups). The mean heart rate values increased maximally by 18 and 26 beats/min in the lower and higher levosimendan dose groups, respectively (p < 0.001 for both groups). The hemodynamic effects peaked at the end of the infusion period and thereafter slowly declined during the follow-up. After the recommended infusion period of 24 hours, the mean heart rate increase was only 2 and 6 beats/min in the lower and higher levosimendan dose groups, respectively. The elimination half-life of levosimendan was approximately 1 hour and of the metabolites 70 to 80 hours. It can be concluded that levosimendan, even administered considerably longer than the recommended 24 hours, was well tolerated. The 7-day infusion induced a prolonged increase in heart rate and a minor decrease in blood pressure. The long-lasting effects are probably explained by the active metabolite.
This article has been cited by other articles:
|
|
 |
|
  F. X. Kleber, T. Bollmann, M. M. Borst, A. Costard-Jackle, R. Ewert, M. Kivikko, T. Petterson, P. Pohjanjousi, S. Sonntag, and G. Wikstrom Repetitive Dosing of Intravenous Levosimendan Improves Pulmonary Hemodynamics in Patients With Pulmonary Hypertension: Results of a Pilot Study J. Clin. Pharmacol., January 1, 2009; 49(1): 109 - 115. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tasouli, K. Papadopoulos, T. Antoniou, I. Kriaras, G. Stavridis, D. Degiannis, and S. Geroulanos Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: importance of early use Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 629 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. De Hert, S. Lorsomradee, S. Cromheecke, and P. J. Van der Linden The Effects of Levosimendan in Cardiac Surgery Patients with Poor Left Ventricular Function Anesth. Analg., April 1, 2007; 104(4): 766 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Montes, D. Echeverri, L. Buitrago, I. Ramirez, J. C. Giraldo, J. D. Maldonado, and J. P. Umana The Vasodilatory Effects of Levosimendan on the Human Internal Mammary Artery Anesth. Analg., November 1, 2006; 103(5): 1094 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Raja and B. S. Rayen Levosimendan in Cardiac Surgery: Current Best Available Evidence Ann. Thorac. Surg., April 1, 2006; 81(4): 1536 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L Earl and J. T Fitzpatrick Levosimendan: A Novel Inotropic Agent for Treatment of Acute, Decompensated Heart Failure Ann. Pharmacother., November 1, 2005; 39(11): 1888 - 1896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dernellis and M. Panaretou Effects of Levosimendan on Restrictive Left Ventricular Filling in Severe Heart Failure: A Combined Hemodynamic and Doppler Echocardiographic Study Chest, October 1, 2005; 128(4): 2633 - 2639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Garcia-Gonzalez, A. Dominguez-Rodriguez, and J. J. Ferrer-Hita Utility of Levosimendan, a New Calcium Sensitizing Agent, in the Treatment of Cardiogenic Shock Due to Myocardial Stunning in Patients With ST-Elevation Myocardial Infarction: A Series of Cases J. Clin. Pharmacol., June 1, 2005; 45(6): 704 - 708. [Full Text] [PDF]
|
|
|
|
|
|
P. Poder, J. Eha, S. Sundberg, S. Antila, M. Heinpalu, I. Loogna, U. Planken, S. Rantanen, and L. Lehtonen Pharmacodynamics and Pharmacokinetics of Oral Levosimendan and Its Metabolites in Patients With Severe Congestive Heart Failure: A Dosing Interval Study J. Clin. Pharmacol., October 1, 2004; 44(10): 1143 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kivikko, L. Lehtonen, W. S. Colucci, and on Behalf of the Study Investigators Sustained Hemodynamic Effects of Intravenous Levosimendan Circulation, January 7, 2003; 107(1): 81 - 86. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
